Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000241 · ClinicalTrials.gov registry record · Phase 2
Flupenthixol Decanoate in Methamphetamine Smoking - 1
A Phase 2 study of Substance-Related Disorders, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
- 1
- Study location
NCT00000241: Completed Phase 2 study of Substance-Related Disorders, sponsored by National Institute on Drug Abuse (NIDA).
NCT00000241 is a Phase 2 study of Substance-Related Disorders that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 58 participants, below the 1,520-participant average among 58 other Substance-Related Disorders trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00000241, a Phase 2 study of Substance-Related Disorders, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the safety and efficacy of flupenthixol decanoate for treatment of methamphetamine dependence. Also, study will compare flupenthixol with desipramine in blocking methamphetamine self-administration.
Conditions Studied
Interventions
- DRUG Flupenthixol
Study Locations (1)
California
- Friends Research Institute - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 1994-02 |
| Est. Completion | 1996-05 |
| Phase | Phase 2 |
What the finished NCT00000241 record still lists
NCT00000241 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 1,520-participant average among 58 other Substance-Related Disorders trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Substance-Related Disorders appearing as the primary indexed condition, and to 1 intervention - of which Flupenthixol is the first listed.
NCT00000241 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00000241 about?
NCT00000241 is a clinical study titled "Flupenthixol Decanoate in Methamphetamine Smoking - 1". The purpose of this study is to evaluate the safety and efficacy of flupenthixol decanoate for treatment of methamphetamine dependence. Also, study will compare flupenthixol with desipramine in blocking methamphetamine self-administration.
What is the current status of trial NCT00000241?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 1994-02. Estimated completion is 1996-05.
What conditions does trial NCT00000241 study?
This clinical trial studies the following conditions: Substance-Related Disorders.
What interventions are being tested in trial NCT00000241?
The interventions under investigation include: Flupenthixol (DRUG).
Who is sponsoring clinical trial NCT00000241?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00000241 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Substance-Related Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00000241's enrollment target sits among peer trials
58 40th of 58 higher than 19 of 58 other Substance-Related Disorders trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Substance-Related Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Transdermal Rotigotine as Adjunct to Behavioral Therapy for Cocaine Use Disorder
RECRUITING · Phase 2
-
GLP-1R Agonist Treatment for Opioid Use Disorder
RECRUITING · Phase 2
-
Cold Water Immersion Modulates Reinforcing Effects of Nitrous Oxide - 2
COMPLETED · Phase 2
-
The Efficacy of Methadyl Acetate (LAAM) and Contingency Management Procedures for Treating Dual Opioid and Cocaine Abuse - 1
COMPLETED · Phase 2
-
Buprenorphine Maintenance for Opiate Dependence - 6
COMPLETED · Phase 2
-
A Laboratory Model for Heroin Abuse Medications - 8
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia